ProShares Short S&P500 (SH)
ARCA ARCA Primary 
XMUN Summary
SH Chart
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
GUANGZHOU, China and LONDON , May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera's third FDA approved product.
Can S&P 500 Bounce Back in Q2? ETFs in Focus
As economic concerns and trade tensions mount, strategists are lowering their outlooks for the S&P 500. A Q2 rebound is less likely for the index.
ProShares Short S&P500 Dividends
| SH 5 months ago | Other | $0.7 Per Share |
| SH 8 months ago Paid | Quarterly | $0.56 Per Share |
| SH 11 months ago Paid | Quarterly | $0.79 Per Share |
| SH 20 Mar 2024 Paid | Quarterly | $0.57 Per Share |
| SH 20 Dec 2023 Paid | Quarterly | $0.94 Per Share |
ProShares Short S&P500 Earnings
| SH 5 months ago | Other | $0.7 Per Share |
| SH 8 months ago Paid | Quarterly | $0.56 Per Share |
| SH 11 months ago Paid | Quarterly | $0.79 Per Share |
| SH 20 Mar 2024 Paid | Quarterly | $0.57 Per Share |
| SH 20 Dec 2023 Paid | Quarterly | $0.94 Per Share |
ProShares Short S&P500 (SH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ProShares Short S&P500 ever had a stock split?
ProShares Short S&P500 Profile
| ARCA Exchange | US Country |
Overview
The company described is a specialized investment fund that focuses on generating daily returns which align with a specified Daily Target. This target is based on the performance of a major U.S. stock market index, which is a comprehensive measure of large-cap U.S. stock performance. The index itself is composed of 500 significant U.S. operating companies and real estate investment trusts (REITs), which are selected by analyzing a variety of factors including liquidity, price, market capitalization, financial viability, and how widely held the stocks are (public float). The strategy of the fund is to invest in financial instruments which, in combination, are believed by ProShare Advisors to achieve the daily performance objectives. It's noteworthy that this fund operates as a non-diversified fund, meaning it may focus its investments more narrowly than a diversified fund might.
Products and Services
- Daily Target Return Investments
This offering centers on the goal of matching the daily return performance of a key stock market index. By targeting the daily returns as per the established Daily Target, the fund appeals to investors seeking consistent, day-to-day investment outcomes based on the large-cap U.S. stock market's performance. The products are crafted using various financial instruments that are chosen for their potential to meet the daily performance goals.
- Investment in Large-Cap Index
Another core aspect of this fund's strategy is its investment in an index that reflects the performance of 500 large-cap U.S. operating companies and real estate investment trusts. This index serves as a benchmark for the U.S. economy’s overall health and is a key indicator for many investors. The selection process for the index components considers factors such as liquidity, market price, market capitalization, financial health, and public float. This service provides investors with a way to participate in the broader U.S. stock market through a single investment product.
Contact Information
